FORM 4 Check this box if no longer subject to Section 16. Form grm gotti														

Stock Option (right to buy) - QRTEB				<u>(4)</u>	03/29/2023	Series B Common Stock	1,498,287 <u>(7)</u>	1,498,287 <u>(7)</u>	D	
Stock Option (right to buy) - QRTEB	107			<u>(4)</u>	03/05/2025	Series B Common Stock		360,087 ⁽⁸⁾	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MAFFEI GREGORY B 12300 LIBERTY BOULEVARD ENGLEWOOD, CO 80112	Х	Х	Chairman of the Board				

Signatures

/s/ Brittany A. Uthoff as Attorney-in-Fact for Gregory B. Maffei	12/14/2021
	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

were approved by the Issuer's board of directors pursuant to Rule 16b-3.

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On November 4, 2021, the Issuer announced that its board of directors declared a special cash dividend in the amount of \$1.25 per common share payable on November 22, 2021, to all holders of record of the Issuer's common stock at the close of business on November 15, 2021 (the "Dividend"). This stock option award was previously reported as an option relating to 3,772,871 shares of the Issuer's Series A common stock at an exercise price of \$4.65 per share and was adjusted as a result of the Dividend. In connection with the Dividend, all common
- (1) 3,772,871 shares of the Issuer's Series A common stock at an exercise price of \$4.65 per share and was adjusted as a result of the Dividend. In connection with the Dividend, all common stock at an exercise price of \$4.65 per share and was adjusted as a result of the Dividend. In connection with the Dividend, all common stock at an exercise price and stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments were approved by the Issuer's board of directors pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended ("Rule 16b-3").
- This stock option award was previously reported as an option relating to 1,190,529 shares of the Issuer's Series A common stock at an exercise price of \$10.34 per share and was adjusted as
 (2) a result of the Dividend. In connection with the Dividend, all common stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments were approved by the Issuer's board of directors pursuant to Rule 16b-3.
- This stock option award was previously reported as an option relating to 352,707 shares of the Issuer's Series A common stock at an exercise price of \$14.62 per share and was adjusted as a
 (3) result of the Dividend. In connection with the Dividend, all common stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments were approved by the Issuer's board of directors pursuant to Rule 16b-3.
- (4) The derivative security is fully vested.

This stock option award was previously reported as an option relating to 46,671 shares of the Issuer's Series B common stock at an exercise price of \$10.25 per share and was adjusted as a (5) result of the Dividend. In connection with the Dividend, all common stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments

- This stock option award was previously reported as an option relating to 270,434 shares of the Issuer's Series B common stock at an exercise price of \$13.56 per share and was adjusted as a result of the Dividend. In connection with the Dividend, all common stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments were approved by the Issuer's board of directors pursuant to Rule 16b-3.
- This stock option award was previously reported as an option relating to 1,283,187 shares of the Issuer's Series B common stock at an exercise price of \$14.27 per share and was adjusted as a result of the Dividend. In connection with the Dividend, all common stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments were approved by the Issuer's board of directors pursuant to Rule 16b-3.
- This stock option award was previously reported as an option relating to 308,183 shares of the Issuer's Series B common stock at an exercise price of \$15.78 per share and was adjusted as a
 (8) result of the Dividend. In connection with the Dividend, all common stock options held by the reporting person were adjusted pursuant to the anti-dilution provisions of the incentive plan under which such award was granted, such that the reporting person received an adjustment to (i) the exercise price and (ii) the number of shares relating to such option. These adjustments were approved by the Issuer's board of directors pursuant to Rule 16b-3.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.